Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseTumor Biomarker DefinedSubgroupHER2+ICD10MeSHNeoplasmsSequenceChemotherapyChemo-substanceTrastuzumab emtansineChemo-substanceTrastuzumab emtansineChemo-substanceTrastuzumab emtansineChemo-substanceTrastuzumab emtansineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaEmetogenicity (MASCC/ESMO)HeadacheHepatotoxicityNeuropathyNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorJhaveri KLDiseaseSolide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Protocols in Revision 1 protocol foundProtocols under revision.Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
